Cemiplimab companion diagnostic - Roche Tissue Diagnostics
Alternative Names: Libtayo companion diagnostic - Roche Tissue Diagnostics; REGN-2810 companion diagnostic - Roche Tissue Diagnostics; SAR-439684 companion diagnostic - Roche Tissue Diagnostics; VENTANA PD-L1 (SP263) Assay for cemiplimab - Roche Tissue DiagnosticsLatest Information Update: 25 Mar 2023
Price :
$50 *
At a glance
- Originator Roche Tissue Diagnostics
- Class Monoclonal antibody diagnostics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Non-small cell lung cancer
Most Recent Events
- 06 Mar 2023 Launched for Non-small cell lung cancer (Diagnosis) in USA (unspecified route)
- 05 Mar 2023 Registered for Non-small cell lung cancer (Diagnosis) in USA (unspecified route)
- 19 Sep 2022 VENTANA PD-L1 (SP 263) Assay receives a CE IVD approval as a companion diagnostic for cemiplimab in Non-small cell lung cancer